These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 30502416)

  • 1. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
    Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
    J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
    Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
    Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa.
    Aarts P; van Huijstee JC; van der Zee HH; van Straalen KR; Prens EP
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):904-909. PubMed ID: 38112226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
    Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
    Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up.
    Dessinioti C; Zisimou C; Tzanetakou V; Stratigos A; Antoniou C
    Clin Exp Dermatol; 2016 Dec; 41(8):852-857. PubMed ID: 27753139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.
    Mendonça CO; Griffiths CE
    Br J Dermatol; 2006 May; 154(5):977-8. PubMed ID: 16634904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clindamycin-Benzoyl Peroxide Gel Compared with Clindamycin Lotion for Hidradenitis Suppurativa: A Randomized Controlled Assessor-Blinded Intra-Patient Pilot Study.
    Aarts P; Reeves JL; Ardon CB; van der Zee HH; Prens EP
    Dermatology; 2023; 239(4):670-674. PubMed ID: 37080176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial.
    Schultheis M; Staubach P; Nikolakis G; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC
    Dermatology; 2022; 238(3):476-486. PubMed ID: 34535610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study.
    Marasca C; Annunziata MC; Villani A; Volpe S; Marasca D; Fabbrocini G
    J Drugs Dermatol; 2019 May; 18(5):437-438. PubMed ID: 31141853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.
    van Straalen KR; Tzellos T; Guillem P; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Jemec GBE; Katoulis AC; Koenig A; Lazaridou E; Marzano AV; Matusiak Ł; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Romaní J; Saunte DM; Skroza N; Stergianou D; Szepietowski J; Trigoni A; Vilarrasa E; van der Zee HH
    J Am Acad Dermatol; 2021 Aug; 85(2):369-378. PubMed ID: 33484766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.
    Scheinfeld N
    Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
    van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
    Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.
    Gener G; Canoui-Poitrine F; Revuz JE; Faye O; Poli F; Gabison G; Pouget F; Viallette C; Wolkenstein P; Bastuji-Garin S
    Dermatology; 2009; 219(2):148-54. PubMed ID: 19590173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.
    Alavi A; Prens EP; Kimball AB; Frew JW; Krueger JG; Mukhopadhyay S; Gao H; Ranganathan U; Ivanoff NB; Hernandez Daly AC; Zouboulis CC
    Br J Dermatol; 2024 Sep; 191(4):508-518. PubMed ID: 38576350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.
    Molinelli E; Brisigotti V; Simonetti O; Sapigni C; D'Agostino GM; Rizzetto G; Giacchetti A; Offidani A
    Dermatol Ther; 2022 Jun; 35(6):e15439. PubMed ID: 35278025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa.
    Yildiz H; Senol L; Ercan E; Bilgili ME; Karabudak Abuaf O
    Int J Dermatol; 2016 Feb; 55(2):232-7. PubMed ID: 26267600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study.
    Ingram JR; Bates J; Cannings-John R; Collier F; Gibbons A; Harris C; Hood K; Howells L; Howes R; Leighton P; Riaz M; Rodrigues J; Stanton H; Thomas KS; Thomas-Jones E
    Health Technol Assess; 2023 Dec; 27(30):1-107. PubMed ID: 38149635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: can some factors influence the response to the treatment?
    Bettoli V; Zauli S; Virgili A
    G Ital Dermatol Venereol; 2016 Apr; 151(2):216-8. PubMed ID: 27068603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 52.